To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Biohaven secures $500m from Sixth Street
Sixth Street has agreed to provide a $500 million term loan facility to Biohaven, a biopharmaceutical company focused on developing treatments for patients with debilitating neurological and neuropsychiatric diseases.
